Redburn
Qize Ding, Ph.D has a diverse work experience spanning several companies and roles. Qize is currently employed at Redburn as an Equity Research Analyst since August 2022. Prior to that, they worked at Jefferies as a Senior Analyst in Healthcare Investment Banking from 2021 to 2022. Qize also worked at PharmaVentures as an Associate Director from 2019 to 2021 and at Citi as a Senior Associate in Equity Research from 2017 to 2019. Qize served as a Scientist at Adaptimmune from 2015 to 2017 and as an Assistant Research Scientist at the University of Oxford from 2010 to 2012.
Qize Ding, Ph.D has pursued a Doctor of Philosophy degree in Cancer Biology with a focus on Targeted cancer therapy at Imperial College London. This educational journey was financially supported by a full scholarship. In addition to their academic achievements, Qize Ding is also a Level 3 candidate for the Chartered Financial Analyst (CFA) certification, offered by the CFA Institute.
Redburn
1 followers
Intelligence is essential for active fund managers and corporates. As part of the Rothschild & Co group, Redburn’s purpose in Research, Execution and Equity Capital Markets is to help all our clients make better investments. Redburn is built upon a commitment to intellectual freedom, commercial research, best execution and premium client service. We were founded in 2003, and have grown from 14 employees to over 200 based in London, Paris, Madrid, New York and Boston. We provide institutional investors with equity research, quantitative and technical analysis, economics research and agency execution in European and North American equity markets, and serve corporates via our Equity Capital Markets division. In addition, Redburn Access also links investors to Redburn's network of industry executives and independent experts.